Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs

1. BroderS

2010 The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antivir Res 85 1 18

2. ContrerasX

LenasiT

PeterlinBM

2006 HIV latency: present knowledge and future directions. Future Virol 1 733 745

3. GeeraertL

KrausG

PomerantzRJ

2008 Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 59 487 501

4. ShenL

SilicianoRF

2008 Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 122 22 28

5. StevensonM

2008 Can HIV be cured? Sci Am 299 78 83

6. FauciA

2008 The future of AIDS research. XVII International AIDS Conference; 3–8 August 2008; Mexico City, Mexico. Avaliable: http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=2912. Accessed 12 May 2010.

7. MarsdenMD

ZackJA

2009 Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 63 7 10

8. RichmanDD

MargolisDM

DelaneyM

GreeneWC

HazudaD

2009 The challenge of finding a cure for HIV infection. Science 323 1304 1307

9. MurphyRL

AutranB

KatlamaC

BruckerG

DebreP

2009 A step ahead on the HIV collaboratory. Science 324 1264 1265

10. StrebhardtK

UllrichA

2008 Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 8 473 480

11. FuchsH

BachranC

2009 Targeted tumor therapies at a glance. Curr Drug Targ 10 89 93

12. DuvicM

TalpurR

2008 Optimizing denileukin diftitox (Ontak (R)) therapy. Future Oncol 4 457 469

13. StasiR

EvangelistaML

BuccisanoF

VendittiA

AmadoriS

2008 Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 34 49 60

14. DadachovaE

CasadevallA

2008 Host and microbial cells as targets for armed antibodies in the treatment of infectious diseases. Curr Opin Investig Drugs 9 184 188

15. GalloRC

MontagnierL

2003 Retrospective: the discovery of HIV as the cause of AIDS. N Eng J Med 349 2283 2285

16. ChaudharyVK

MizukamiT

FuerstTR

FitzGeraldDJ

MossB

1988 Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 335 369 372

17. TillMA

GhetieV

GregoryT

PatzerEJ

PorterJP

1988 HIV-infected cells are killed by rCD4-ricin A chain. Science 242 1166 1168

18. PincusSH

WehrlyK

ChesebroB

1989 Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol 142 3070 3075

19. AulloP

AlcamiJ

PopoffMR

KlatzmannDR

MurphyJR

1992 A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. EMBO J 11 575 583

20. FinbergRW

WahlSM

AllenJB

SomanG

StromTB

1991 Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 252 1703 1705

21. ZhangL

WatersC

NicholsJ

CrumpackerC

1992 Inhibition of HIV-1 RNA Production by the Diphtheria Toxin- Related IL-2 Fusion Proteins DAB(486)IL-2 and DAB(389)IL-2. J Acquir Immune Defic Syndr 5 1181 1187

22. RamiloO

BellKD

UhrJW

VitettaES

1993 Role of CD25+ and CD25- T-cells in acute HIV-infection invitro. J Immunol 150 5202 5208

23. McCoigC

Van DykeG

ChouCS

PickerLJ

RamiloO

1999 An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proc Natl Acad Sci U S A 96 11482 11485

24. WolfP

Elsasser-BeileU

2009 Pseudomonas exotoxin A: From virulence factor to anti-cancer agent. Int J Med Microbiol 299 161 176

25. PastanI

HassanR

FitzGeraldDJ

KreitmanRJ

2006 Immunotoxin therapy of cancer. Nat Rev Cancer 6 559 565

26. BergerEA

ChaudharyVK

ClouseKA

JaraquemadaD

NicholasJA

1990 Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions. AIDS Res Hum Retroviruses 6 795 804

27. AshornP

MossB

BergerEA

1992 Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins. J Acquir Immune Defic Syndr 5 70 77

28. BeraTK

KennedyPE

BergerEA

BarbasCFI

PastanI

1998 Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol Med 4 384 391

29. BergerEA

ClouseKA

ChaudharyVK

ChakrabartiS

FitzGeraldDJ

1989 CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc Natl Acad Sci U S A 86 9539 9543

30. AshornP

MossB

WeinsteinJN

ChaudharyVK

FitzGeraldDJ

1990 Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci U S A 87 8889 8893

31. AshornP

EnglundG

MartinMA

MossB

BergerEA

1991 Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. J Infect Dis 163 703 709

32. KennedyPE

MossB

BergerEA

1993 Primary HIV-1 isolates refractory to neutralization by soluble CD4 are potently inhibited by CD4-Pseudomonas exotoxin. Virology 192 375 379

33. VerhoefJ

GekkerG

EriceA

PetersonPK

BalfourHH

1992 Quantitative assay for testing susceptibility of HIV isolates to zidovudine and sCD4 (178)-PE40. Eur J Clin Microbiol Infect Dis 11 715 721

34. WintersMA

MeriganTC

1993 Continuous Presence of CD4-PE40 Is Required for Antiviral Activity Against Single-Passage HIV Isolates and Infected Peripheral Blood Mononuclear Cells. AIDS Res Hum Retroviruses 9 1091 1096

35. GorryPR

ChurchillM

CroweSM

CunninghamAL

GabuzdaD

2005 Pathogenesis of macrophage tropic HIV-1. Curr HIV Res 3 53 60

36. ColemanCM

WuL

2009 HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 6 51

37. DaveyRT

BoenningCM

HerpinBR

BattsDH

MetcalfJA

1994 Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 170 1180 1188

38. RamachandranRV

KatzensteinDA

WoodR

BattsDH

MeriganTC

1994 Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. J Infect Dis 170 1009 1013

39. BergerEA

MossB

PastanI

1998 Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proc Natl Acad Sci U S A 95 11511 11513

40. KreitmanRJ

WilsonWH

BergeronK

RaggioM

Stetler-StevensonM

2001 Efficacy of the anti-CD22 recombinant immunotoxin BL-22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345 241 247

41. KreitmanRJ

Stetler-StevensonM

MarguliesI

NoelP

FitzGeraldDJP

2009 Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27 2983 2990

42. BarbasCF

HuD

DunlopN

SawyerL

CababaD

1994 In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A 91 3809 3813

43. KennedyPE

BeraTK

WangQC

GalloM

WagnerW

2006 Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. J Leukoc Biol 80 1175 1182

44. OndaM

NagataS

TsutsumiY

VincentJJ

WangQC

2001 Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 61 5070 5077

45. GoldsteinH

Pettoello-MantovaniM

BeraTK

PastanIH

BergerEA

2000 Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-scid-hu mice. J Infect Dis 181 921 926

46. UberlaK

StahlhennigC

BottigerD

MatzrensingK

KaupFJ

1995 Animal model for the therapy of acquired-immunodeficiency syndrom with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A 92 8210 8214

47. IgarashiT

BrownCR

EndoY

Buckler-WhiteA

PlishkaR

2001 Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4(+) t cells by a highly pathogenic simian immunodeficiency virus/hiv type 1 chimera (shiv): implications for hiv-1 infections of humans. Proc Natl Acad Sci U S A 98 658 663

48. AmbroseZ

PalmerS

BoltzVF

KearneyM

LarsenK

2007 Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol 81 12145 12155

49. Van RompayKKA

JohnsonJA

BlackwoodEJ

SinghRP

LipscombJ

2007 Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 4 25

50. DinosoJB

RabiSA

BlanksonJN

GamaL

MankowskiJL

2009 A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 83 9247 9257

51. DinosoJB

KimSY

WiegandAM

PalmerSE

GangeSJ

2009 Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 106 9403 9408

52. JonesJ

McMahonD

WiegandA

KearneyM

PalmerS

2009 No decrease in residual viremia during raltegravir intensification in patients on standard ART. 16th Conference on Retroviruses and Opportunistic Infections; 8–11 February 2009; Montreal, Canada. CROI 2009. [Abstract 423b]

53. BuzonM

LlibreJ

DomingoP

ParedesR

PalmerS

2009 Transient increase in episomal viral cDNA following raltegravir intensification of a stable HAART Regimen. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada. CROI 2009. [Abstract 423a]

54. BaileyJR

SedaghatAR

KiefferT

BrennanT

LeePK

2006 Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4(+) T cells. J Virol 80 6441 6457

55. BrennanTP

WoodsJO

SedaghatAR

SilicianoJD

SilicianoRF

2009 Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4(+) T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 83 8470 8481

56. BrooksDG

HamerDH

ArlenPA

GaoLY

BristolG

2003 Molecular characterization, reactivation, and depletion of latent HIV. Immunity 19 413 423

57. MarsdenMD

XuJ

HamerD

ZackJA

2008 Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages. AIDS Res Hum Retroviruses 24 1399 1404

58. JohanssonS

GoldenbergDM

GriffithsGL

WahrenB

HinkulaJ

2006 Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. AIDS 20 1911 1915

59. DadachovaE

PatelMC

ToussiS

ApostolidisC

MorgensternA

2006 Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med 3 e427 doi:10.1371/journal.pmed.0030427

60. OndaM

BeersR

XiangL

NagataS

WangQC

2008 An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 105 11311 11316

61. McHughL

HuS

LeeBK

SantoraK

KennedyPE

2002 Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis. J Biol Chem 277 34383 34390

62. PincusSH

FangH

WilkinsonRA

MarcotteTK

RobinsonJE

2003 In vivo efficacy of anti-glycoprotein 41, but not anti- glycoprotein 120, immunotoxins in a mouse model of hiv infection. J Immunol 170 2236 2241

63. RootMJ

HamerDH

2003 Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein. Proc Natl Acad Sci U S A 100 5016 5021

64. MontefioriD

SattentauQ

FloresJ

EsparzaJ

MascolaJ

2007 Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 4 e348 doi:10.1371/journal.pmed.0040348

65. WalkerLM

PhogatSK

Chan-HuiPY

WagnerD

PhungP

2009 Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 285 289

66. BrenchleyJM

DouekDC

2008 HIV infection and the gastrointestinal immune system. Mucosal Immunol 1 23 30

67. ChunTW

NickleDC

JustementJS

MeyersJH

RobyG

2008 Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197 714 720

68. LundgrenJD

BabikerA

El-SadrW

EmeryS

GrundB

2008 Inferior clinical outcome of the CD4(+) cell count guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4(+) cell counts and HIV RNA levels during follow-up. J Infect Dis 197 1145 1155